Extended Research →
Verdict, decision matrix, deep dives, sourcing notes & full sources

Ashwagandha KSM-66

Root-only ashwagandha extract standardized to ~5% withanolides, licensed by Ixoreal Biomed (India), and the substrate of most of the high-quality T-boost and athletic-performance trials in the ashw… | Compound

Aliases (4)
KSM-66 · Ixoreal Ashwagandha · KSM-66 Ashwagandha extract · Withania somnifera root extract
TYPICAL DOSE
300 mg BID with meals, or 600 mg AM with breakfast
ROUTE
CYCLE
STORAGE
Did you know? You can suggest edits to improve this compound's information.
Submitted via email — no account required.
Suggest an edit
Overview TL;DR

Root-only ashwagandha extract standardized to ~5% withanolides, licensed by Ixoreal Biomed (India), and the substrate of most of the high-quality T-boost and athletic-performance trials in the ashwagandha literature. Reputation for being more pro-energy / less sedating than Sensoril, with a stronger T-modulation track record. For Dylan: OPTIONAL-ADD low priority; STRONG-CANDIDATE for stress-prone or T-low-normal archetypes. Parent file ashwagandha.md has the full mechanism, evidence, and decision matrix — this file focuses on KSM-66-specific differences vs. Sensoril and other extracts.

Mechanism of action

Same general mechanism as parent ashwagandha entry. KSM-66-specific notes:

  • Root-only extraction: Excludes leaf material. Leaf contains higher withaferin A (more potent immune-modulatory and cytotoxic withanolide); root has more withanolide A, withanoside IV/VI (less potent but better-tolerated).
  • ~5% withanolides standardization: Lower percentage than Sensoril's ~10%, but root-only positions the withanolide profile differently.
  • Patented green chemistry extraction: No alcohol or organic solvent — milk and water based. Marketing claim, but the chemistry is verifiable.
  • Pharmacokinetics: Withanolide A peak plasma 4-6 h post-dose; half-life ~6-8 h supports BID dosing.
Pharmacokinetics Approximate
t½: 6-8 h
100% 50% 0% 0 9h 18h 26h 35h Peak

Approximate decay curve drawn from the half-life mention(s) in the source notes. Real PK data not yet ingested per compound.

What to expect Generic
  1. 1
    Week 1
    Tolerability and dose-response.
  2. 2
    Week 2-4
    Early effect window.
  3. 3
    Week 4-8
    Peak benefit assessment.
  4. 4
    Week 8+
    Cycle decision point.
Side effects + safety

Same as parent ashwagandha entry. KSM-66-specific notes:

  • Lower withaferin A than Sensoril → potentially lower autoimmune-flare risk (theoretical)
  • GI upset somewhat less than Sensoril at equivalent withanolide load (anecdotal)
  • Hepatotoxicity case reports exist for ashwagandha generally; KSM-66 has fewer reports than unstandardized products but background rate non-zero
Interactions4 compounds
  • rhodiolaSynergistic
    (Dylan's V4): AM-rhodiola + PM-ashwagandha is a classic adaptogen pairing
  • magnesium-glycinateSynergistic
    (Dylan's V4): HPA-axis support
  • l-theanineSynergistic
    (Dylan's V4): Additive calm without sedation
  • fish oil / DHASynergistic
    (Dylan's V4): Independent neuroprotection
References5 sources
Was this helpful?
Your feedback shapes what we research deeper.
Continue: Extended Research →
Our verdict, decision matrix, deep dives, controversies, sources